INTRODUCTION
The misuse of opioids has led to dramatic increases in opioid-related mortality with opioid-related deaths increasing by 345% from 2001 to 2016 in the USA. 1, 2 The marketing of opioids by the pharmaceutical industry to providers is well documented, with 1 in 12 US physicians receiving opioid-related industry payments. 3 However, it is unclear how or even if pharmaceutical industry payments are related to opioid-related deaths, or if disparities exist in marketing efforts for at-risk populations. We examined if opioid-related industry payments to healthcare providers were associated with opioidrelated deaths by US county in 2016.
METHODS
We used the Centers for Medicare & Medicaid Services (CMS) Open Payments General Payment 2016 database to examine industry (non-research, non-ownership related) payments given by county to providers in association with opioid drugs, as listed on the CMS Opioid Drug List. 4 We obtained opioid-related deaths in 2016 by county from the Centers for Disease Control and Prevention WONDER Multiple Cause of Death database by classifying underlying cause of death related to poisoning (ICD-10 codes X40-X44, X60-64, X85, and Y10-Y14) and multiple cause of death codes related to opioids (ICD-10 codes T40.0-T40.4 and T40.6). 5 To account for variation in county size, we adjusted opioid-related deaths and opioid-related open payments by county population in 2016 as provided by the WON-DER database. We used the Spearman rank correlation to analyze the association of the per capita opioidrelated open payments and per capita opioid-related deaths by county. Geographic data of payments and deaths were mapped using geographic information system technology (ArcGIS; Redlands, CA). 6 This study utilized public databases and therefore was exempt from Institutional Review Board approval.
RESULTS
In 2016, there were 42,249 opioid-related deaths in the country with an overall rate of 13.1 deaths per 100,000 population. There was a statistically significant association between per capita opioid-related industry payments and per capita opioidrelated deaths by county (rho = 0.08, P < 0.001) (Fig. 1 ). An increase in $10,000 opioid-related industry payments per 100,000 population was associated with an increase in 0.89 opioid-related deaths per 100,000 population. The distribution of opioid-related deaths and opioid-related industry payments is mapped in Figure 2 .
DISCUSSION
Our study demonstrated that US counties that receive more opioid-related industry payments had more opioidrelated deaths. To our knowledge, this is the first study investigating industry payments and mortality data. While it is tempting to conclude that these payments caused more indiscriminate opioid prescribing and subsequent overdoses, there are also alternate explanations.
T h e c a u s a l a r r o w m a y p o i n t i n t h e o t h e r direction-companies may direct payments to areas where there are higher rates of opioid prescribing. There may be unresolved confounding or ecologic effects. Nonetheless, the results are very concerning and call for further investigation. In the midst of a nationwide opioid crisis, it is imperative to rigorously consider the risks and benefits of industry payments on opioid abuse in at-risk populations.
